CO5241354A1 - Terapia de combinacio para vhc - Google Patents
Terapia de combinacio para vhcInfo
- Publication number
- CO5241354A1 CO5241354A1 CO00028688A CO00028688A CO5241354A1 CO 5241354 A1 CO5241354 A1 CO 5241354A1 CO 00028688 A CO00028688 A CO 00028688A CO 00028688 A CO00028688 A CO 00028688A CO 5241354 A1 CO5241354 A1 CO 5241354A1
- Authority
- CO
- Colombia
- Prior art keywords
- combination therapy
- ribavirin
- hcv combination
- hcv
- interferon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Abstract
Se describen los métodos para tratar pacientes que tienen infecciones virales susceptibles, especialmente la infección por hepatitis C crónica administrando a dicho paciente una cantidad terapéuticamente efectiva de una terapia de combinación de interferón-alfa y ribavirina durante un periodo suficiente como para mejorar la hemólisis relacionada con la ribavirina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29468799A | 1999-04-19 | 1999-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5241354A1 true CO5241354A1 (es) | 2003-01-31 |
Family
ID=23134504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00028688A CO5241354A1 (es) | 1999-04-19 | 2000-04-18 | Terapia de combinacio para vhc |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1046399A1 (es) |
JP (1) | JP2002542202A (es) |
CN (1) | CN1355708A (es) |
AR (1) | AR023541A1 (es) |
AU (1) | AU4463300A (es) |
BR (1) | BR0009840A (es) |
CA (1) | CA2306039A1 (es) |
CO (1) | CO5241354A1 (es) |
HU (1) | HUP0200942A3 (es) |
MX (1) | MXPA00003974A (es) |
NO (1) | NO20015059L (es) |
PE (1) | PE20010284A1 (es) |
WO (1) | WO2000062799A1 (es) |
ZA (1) | ZA200108571B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
CZ20022825A3 (cs) | 2000-02-18 | 2003-05-14 | Shire Biochem Inc. | Analoga nukleosidů pro použití při léčení nebo prevenci infekcí způsobených flavivirem |
WO2002036072A2 (en) * | 2000-11-03 | 2002-05-10 | Biomedicines, Inc. | Method for short-term and long-term drug dosimetry |
ITMI20011863A1 (it) * | 2001-09-05 | 2003-03-05 | Zambon Spa | Associazione di farmaci contro il virus dell'influenza |
WO2003024461A1 (en) * | 2001-09-20 | 2003-03-27 | Schering Corporation | Hcv combination therapy |
US20040022873A1 (en) * | 2001-11-09 | 2004-02-05 | Guilford F. Timothy | Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses |
EP1369120B1 (en) * | 2002-06-03 | 2007-02-14 | National Health Research Institutes | Treatment of flavivirus infection |
EP1567172A2 (en) * | 2002-11-29 | 2005-08-31 | GPC Biotech AG | Formulations useful against hepatitis c virus infections |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
JP4570563B2 (ja) * | 2003-02-21 | 2010-10-27 | 持田製薬株式会社 | リバビリン/インターフェロン併用療法の副作用軽減剤 |
WO2005016370A1 (en) * | 2003-08-13 | 2005-02-24 | Howard J. Smith & Associates Pty Ltd | Method of treating viral infections |
WO2005120479A1 (en) * | 2004-06-09 | 2005-12-22 | Gpc Biotech Ag | Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US8299025B2 (en) | 2005-02-03 | 2012-10-30 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
KR101106510B1 (ko) | 2006-05-30 | 2012-01-20 | 인타르시아 세라퓨틱스 인코포레이티드 | 투피스, 내부채널 삼투압 전달 시스템 유동 조절기 |
KR101200728B1 (ko) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | 삼투성 전달 시스템 및 피스톤 조립체 |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
HUE035862T2 (en) | 2009-09-28 | 2018-05-28 | Intarcia Therapeutics Inc | Rapid development and / or completion of substantially steady-state drug delivery |
MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US20130129680A1 (en) * | 2011-11-23 | 2013-05-23 | Thomas Christian Lines | Method for treating hepatitis c virus infection using quercetin-containing compositions |
AU2013293087B2 (en) | 2012-07-24 | 2017-08-31 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK) |
KR20150080592A (ko) | 2012-11-02 | 2015-07-09 | 파마시클릭스, 인코포레이티드 | Tec 패밀리 키나제 억제제 애쥬번트 요법 |
WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
EP3302354B1 (en) | 2015-06-03 | 2023-10-04 | i2o Therapeutics, Inc. | Implant placement systems |
BR112018073511A2 (pt) | 2016-05-16 | 2019-03-26 | Intarcia Therapeutics, Inc. | polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
CN110225762A (zh) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | 包括glp-1受体激动剂的连续施用和药物的共同施用的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5157998A (en) * | 1996-11-01 | 1998-05-29 | Thomas Najarian | Methods and compositions for treatment of hepatitis c infection |
-
2000
- 2000-04-18 JP JP2000611935A patent/JP2002542202A/ja active Pending
- 2000-04-18 EP EP20000303246 patent/EP1046399A1/en not_active Withdrawn
- 2000-04-18 CA CA002306039A patent/CA2306039A1/en not_active Abandoned
- 2000-04-18 BR BR0009840-0A patent/BR0009840A/pt not_active IP Right Cessation
- 2000-04-18 HU HU0200942A patent/HUP0200942A3/hu unknown
- 2000-04-18 AR ARP000101815A patent/AR023541A1/es unknown
- 2000-04-18 CO CO00028688A patent/CO5241354A1/es not_active Application Discontinuation
- 2000-04-18 AU AU44633/00A patent/AU4463300A/en not_active Abandoned
- 2000-04-18 CN CN00808831A patent/CN1355708A/zh active Pending
- 2000-04-18 WO PCT/US2000/010240 patent/WO2000062799A1/en active Application Filing
- 2000-04-19 PE PE2000000373A patent/PE20010284A1/es not_active Application Discontinuation
- 2000-04-19 MX MXPA00003974A patent/MXPA00003974A/es unknown
-
2001
- 2001-10-18 NO NO20015059A patent/NO20015059L/no not_active Application Discontinuation
- 2001-10-18 ZA ZA200108571A patent/ZA200108571B/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0200942A2 (hu) | 2002-07-29 |
PE20010284A1 (es) | 2001-03-05 |
NO20015059L (no) | 2001-12-19 |
BR0009840A (pt) | 2002-01-08 |
MXPA00003974A (es) | 2002-03-08 |
CA2306039A1 (en) | 2000-10-19 |
WO2000062799A1 (en) | 2000-10-26 |
CN1355708A (zh) | 2002-06-26 |
HUP0200942A3 (en) | 2003-03-28 |
ZA200108571B (en) | 2003-01-20 |
EP1046399A1 (en) | 2000-10-25 |
JP2002542202A (ja) | 2002-12-10 |
NO20015059D0 (no) | 2001-10-18 |
AR023541A1 (es) | 2002-09-04 |
AU4463300A (en) | 2000-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5241354A1 (es) | Terapia de combinacio para vhc | |
AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
HUP0100092A2 (hu) | Kombinációs terápia kimutatható HCV-RNS eradikációjára krónikus hepatitis-C fertőzött betegekben | |
MY133891A (en) | Polyethylene glycol modified interferon therapy | |
DK0911033T4 (da) | Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis | |
NO20073632L (no) | Behandling av hepatitt C med interferon-beta i en asiatisk populasjon | |
AR023824A1 (es) | Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado. | |
NZ588655A (en) | Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin | |
PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
MD1875F1 (en) | Method of treatment of the acute viral hepatitis B | |
AR036697A1 (es) | Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento | |
DK1251850T3 (da) | Anvendelse af et kombinationspræparat i cancerbehandling | |
ECSP003446A (es) | Terapia de combinacion para vhc | |
EA200501569A1 (ru) | Лечение или профилактика респираторных вирусных инфекций с использованием пептидов альфа-тимозина | |
WO2005058237A3 (en) | Treatment of aids | |
CO5160259A1 (es) | Interferon alfa pegilado en la terapia contra el hiv | |
CO5170412A1 (es) | Tratamiento del carcinoma de celula renal | |
EA199800770A1 (ru) | Лекарственный препарат для терапевтического лечения вирусного гепатита | |
DK1311279T3 (da) | Behandling af hepatitis C med thymosin, interferon og ribavirin | |
TH46769A (th) | การรักษาร่วมของ hcv | |
GB9903091D0 (en) | Therapeutic nucleoside compound | |
DK1311286T3 (da) | Behandling af hepatitis C med thymosin og pegyleret interferon | |
ECSP003373A (es) | Terapia contra el hiv | |
TH53874A3 (th) | การบำบัดรักษา hcv แบบผสมผสานโดยการเหนี่ยวนำด้วยไรบาไวรินและอินเทอฟีรอนอัลฟาชนิดเพกิเลเตด | |
TH54147B (th) | ไมโคฟิโนเลท โมฟิทิล โนการเข้าร่วมกับ PEG-IFN -a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |